Gilead Sciences NASDAQ: GILD expects HIV and oncology to drive growth through the rest of the decade while it builds an inflammation business for the 2030s, executives said at a London healthcare conference.
Chairman and CEO Dan O’Day said the company was coming off its strongest growth in more than a decade in the third quarter, citing contributions from HIV, cancer treatment TRODELVY and LIVDELZI, a treatment for primary biliary cholangitis. He said Gilead is working to diversify its HIV treatment business before the 2036 patent expiration for BIKTARVY.
Inflammation strategy centers on combinations
O’Day said Gilead’s inflammation strategy includes developing oral medicines that could be used alone or combined with other treatments. He pointed to phase 2 data for the company’s oral alpha-4-beta-7 candidate, saying it showed potential for injectable-level efficacy in a pill, with a favorable tolerability profile.
Gilead plans to pursue the candidate as a monotherapy and in combinations for inflammatory bowel disease, including ulcerative colitis. The company recently in-licensed an oral IL-23 candidate that could be one combination partner, though O’Day said Gilead could also consider other IL-23 treatments or different mechanisms, including assets owned by other companies.
Chief Financial Officer Andy Dickinson said the IL-23 candidate has the potential for once-monthly oral dosing and could be studied across disease severities. O’Day said its potency could make it suitable for eventual co-formulation with another drug, while cautioning that it was too early to say exactly how that would work.
Gilead’s inflammation portfolio also includes an IRAK4 small-molecule candidate and gamgertamig, a B-cell depleter being developed with Lakefront Biotherapeutics. O’Day said gamgertamig could be the company’s first potential inflammation launch, possibly in the early 2030s.
Oncology and dealmaking
O’Day said Gilead remains confident in the potential of the Tubulis antibody-drug conjugate platform, including its lead NaPi2b approach in ovarian cancer. He said the platform’s tightly bound linker could make its treatments easier to combine with chemotherapy or other agents than antibody-drug conjugates with looser linkers.
Gilead is pursuing programs in both platinum-resistant and platinum-sensitive ovarian cancer and sees potential applications in other cancers, O’Day said. He added that the company feels good about the dose planned for ovarian cancer and expects to share more data next year, though he did not specify when. Gilead would also consider outside partners for combinations involving Tubulis assets, he said.
Dickinson said Gilead continues to look for late-stage assets that could add revenue and diversification, but that its stronger pipeline has raised the bar for deals. He said the company expects to generate roughly $13 billion in free cash flow this year and has the flexibility to add assets over time.
“We will be very disciplined in doing that,” Dickinson said, adding that Gilead has time for a “steady, consistent cadence of deals.”
Long-acting HIV treatments and prevention
O’Day said he expects HIV treatment to shift toward longer-acting regimens and that Gilead has up to five additional long-acting treatment launches planned before BIKTARVY’s patent expiry. The company is studying monthly and six-month injectable approaches, as well as another candidate on a four-month schedule.
For HIV prevention, O’Day said the six-month injectable YEZTUGO had started strongly. He said Gilead expects to launch a once-weekly oral version in the first quarter of next year and sees potential for a once-yearly injectable in 2028.
O’Day said the weekly oral option could have faster access and reimbursement than the injectable because it would be covered through pharmacy benefits. He estimated that about 70% of people would have immediate access and said the product could both draw users from existing prevention regimens and expand the market.
About Gilead Sciences (NASDAQ:GILD)
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.